QuantiFERON Change During Anti-tuberculosis Medication

The aim of this study is to evaluate the change of QuantiFERON-TB gold in tube assay (QFT) during the treatment of active tuberculosis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Tuberculosis Actinomycetales Infections Bacterial Infections Bacterial Infections and Mycoses Gram-Positive Bacterial Infections Infections Interferon-gamma Release Assay Mycobacterium Infections

Sex eligibility

All sexes

Study type

Observational

Primary location

Armed Forces Capital Hospital

Seongnam-si, Gyeonggi-do, 463-040, South Korea

About this study

Patients with active pulmonary tuberculosis are enrolled and, QFTs are performed for each subjects before treatment and 1, 3, 6 months after treatment. Investigators check the level of interferon-gamma, and reversion and conversion of this test.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All subjects with active tuberculosis

Exclusion criteria

Subjects who cannot complete study
Subjects who have taken anti-tuberculosis medication for more than a month before visit of our hospital

Sponsors and collaborators

Lead sponsor

Armed Forces Capital Hospital, Republic of Korea

Other Gov

Registry information

Official study title

The Change in Level of Interferon-gamma Assay in Active Tuberculosis Patients During Treatment

Important dates

Study start: 2008
Primary completion: 2010
Study completion: 2010
First posted: Dec 24, 2009
Registry last updated: Jun 14, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed